No anaphylaxis events occurred within the 3-day risk period postvaccination in either LAIV recipients or any control group. Within 3 days of LAIV vaccination, there were 2 events of urticaria, both in the clinic setting; urticaria did not occur at a significantly higher or lower rate in LAIV recipients relative to control groups in any comparison. After a post hoc adjustment for multiple comparisons, 48 of 257 incidence rate comparisons remained statistically significant

(Table 4). Events occurring at a higher rate after LAIV were benign lesion, obesity and vision disorder. Events occurring at a lower rate after LAIV included any asthma or wheezing event, any hospitalization/death, any SAE, addiction, AIDS, back pain, diabetes, gestational diabetes, hypertension, neck pain, pelvic pain, postsurgical state, pregnancy (delivery and examination), and systemic Selleck Galunisertib lupus erythematosus (SLE). Well visits and any event were CDK inhibitor drugs increased after LAIV in comparison to those unvaccinated and decreased after LAIV in comparison to those vaccinated with TIV. No events were increased in the within-cohort analysis after adjustment for multiple comparisons. A total of 91 pregnancies occurred in 90 LAIV recipients; 80

had information on the timing of conception relative to vaccination. Eleven subjects (14%) were vaccinated on or before their last menstrual period, 50 (63%) in the first trimester, 14 (18%) in the second trimester and 5 (6%) in their third trimester. Of 88 pregnancies with known outcomes, 17 had elective abortions, 13 had spontaneous abortions, 3 had ectopic pregnancies and 55 had live births. Fifty-four of the 55 live births had additional information available and were described as a healthy child (n = 22), no adverse event with delivery (n = 27), premature delivery (n = 3; 36 weeks, 35 weeks, and twins born at 25 weeks gestational age), large for gestational age, and clinodactyly (n = 1 each). This large,

postlicensure safety analysis Dichloromethane dehalogenase of LAIV did not identify any new safety concerns in eligible adults. SAEs within 42 days of vaccination were uncommon and the most common diagnoses identified (pancreatitis, trauma, cholelithiasis, urinary tract infection) are common causes of hospitalization among adults [17]. Only 3 SAEs were considered to be possibly or probably related to the vaccine (migraine/sinusitis and two events of Bell’s palsy), all of which have been previously reported after vaccination with LAIV [14]. Anaphylaxis after LAIV was not seen and urticaria within 3 days of vaccination was uncommon. This study supports prelicensure studies and a postlicensure analysis conducted by the Vaccine Adverse Events Reporting System (VAERS), which did not identify any unexpected serious risks when LAIV was used in approved populations [8] and [18].